Conjugation of the Fn14 Ligand to a SMAC Mimetic Selectively Suppresses Experimental Squamous Cell Carcinoma in Mice

• Published in: Journal of investigative dermatology Vol. 143; no. 2; pp. 242 - 253.e6
• Main Authors: Wang, Xiaoyu, Lu, Mei, Gu, Hanjiang, Xiao, Tong, Hu, Guanglei, Luo, Mai, Guo, Xingyi, Xia, Yumin
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.02.2023
• Subjects: Animals; Carcinoma, Squamous Cell - drug therapy; Cell Line, Tumor; Cytokine TWEAK; Humans; Inhibitor of Apoptosis Proteins; Ligands; Mice; Receptors, Tumor Necrosis Factor - chemistry; Receptors, Tumor Necrosis Factor - metabolism; TWEAK Receptor; TNFR; IAPs; SCC
• ISSN: 0022-202X; 1523-1747
• DOI: 10.1016/j.jid.2022.08.039

The mimetic of SMAC induced cell death in cancers by depleting the inhibitor of apoptosis proteins. Recent studies showed that Fn14 is overexpressed in the cells of squamous cell carcinoma (SCC), providing a promising candidate target for selective antitumor therapy. In this study, we conjugated a small-molecule SMAC mimetic MV1 to the ligand of Fn14, TWEAK. Our results showed that TWEAK‒MV1 conjugate retained adequate binding specificity to Fn14-positive SCC cells in vitro and accumulated selectively in tumor tissue of cutaneous SCC xenografts mice after intraperitoneal administration. This conjugation compound exhibited remarkable effectiveness in suppressing tumor growth and extending overall survival without causing significant side effects in SCC xenograft mice. Moreover, TWEAK‒MV1 conjugate greatly enhanced both apoptotic and necroptotic cell death both in vitro and in vivo, accompanied by a cellular inhibitor of apoptosis proteins degradation as well as activation of receptor-interacting protein kinase. Taken together, our preclinical data suggested that the designed conjugation compound of TWEAK and MV1 might provide a potential therapeutic strategy for cutaneous SCC with improved antitumor efficacy and negligible toxicity. [Display omitted]